Table 2.
No. | Gender | Age, years | Group | SAE | Diagnostic date | Treatments | Relationship with transplantation | Outcome | Death time |
---|---|---|---|---|---|---|---|---|---|
2 | Male | 37 | Placebo | Seizure | 11th month | Oral drugs | No | Survival | |
3 | Male | 45 | Placebo | Seizure | 11th month | Oral drugs | No | Survival | |
4 | Male | 32 | BMSCs | Deep vein thrombosis | 6th month | Thrombolysis | No | Survival | |
11 | Male | 69 | Placebo | Parkinson's syndrome | 10th month | Oral drugs | No | Dead | 22nd month |
16 | Male | 74 | Placebo | Arrhythmia | 3rd month | Hospitalized | No | Dead | 4th month |
1 | Female | 47 | Placebo | Recurrent stroke | 42nd month | Hospitalized | No | Dead | 42nd month |
11 | Male | 69 | Placebo | Cancer | 20th month | Hospitalized | No | Dead | 22nd month |
Abbreviations: BMSCs, bone marrow stromal cells; SAE, serious adverse events.